抗血栓药物与老年创伤性脑损伤:出血模式与结局
本研究纳入单中心24个月内1365例65岁以上头部创伤患者,其中724例使用抗血栓药物。调整协变量后,抗血小板药物使用与创伤性脑损伤风险相关;在731例TBI患者中,使用抗血栓药物者颅内出血率、出院时功能依赖和死亡率均更高。华法林单药及华法林联合抗血小板治疗与出血进展风险升高相关;双联抗血小板、华法林和DOAC使用与死亡率升高相关。
要点
- 老年头部创伤患者使用抗血栓药物者颅内出血、功能依赖和死亡率更高。
- 华法林单药及华法林联合抗血小板治疗与随访CT出血进展风险升高相关。
- 单用抗血小板药物与死亡率无关,但阿司匹林联合氯吡格雷与死亡率升高相关。
核心结论
- 使用抗血栓药物的老年创伤患者,尤其是联合治疗者,颅内出血和不良结局风险升高。
- 华法林是随访扫描出血进展的预测因素,而单用抗血小板药物与死亡率无关。
- DOAC使用者颅内出血进展率较低,出院时功能依赖的存活者较少,是跌倒高风险患者中华法林的更安全替代。
研究设计与样本
- 回顾性研究,收集单中心24个月内所有65岁以上头部创伤患者的数据。
- 共纳入1365例患者,其中724例使用抗血栓药物,641例未使用。
- 抗血栓药物包括抗血小板药(阿司匹林、氯吡格雷)和/或抗凝药(华法林、DOAC)。
主要发现
- 在所有头部创伤患者中,调整协变量后,创伤性脑损伤风险与抗血小板药物使用相关。
- 在731例TBI患者中,使用抗血栓药物者颅内出血率更高(p <0.0001)。
- 使用抗血栓药物者出院时功能依赖(GOSE评分≤4)率更高(p <0.0001)。
- 使用抗血栓药物者死亡率更高(p <0.0001)。
- 随访CT显示出血进展率升高见于华法林单药治疗(OR 5.30,p <0.0001)和华法林+抗血小板治疗(OR 6.15,p = 0.0011)。
关键数值与推荐
- 死亡风险与单用抗血小板药物无关,但与双联抗血小板药物(OR 4.66,p = 0.0056)、华法林(OR 5.18,p = 0.0003)和DOAC使用(OR 5.09,p = 0.0149)显著相关。
- 华法林和DOAC使用者的死亡率相当;但DOAC使用者颅内出血进展率较低,出院时功能依赖的存活者较少。
临床怎么用
- 对老年头部创伤患者,应详细询问抗血栓药物使用史,尤其是联合治疗。
- 使用华法林或联合抗血栓治疗的患者需警惕颅内出血进展,密切随访CT。
- 对于跌倒高风险患者,DOAC可能是比华法林更安全的抗凝选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Among the elderly, use of antithrombotics (ATs), antiplatelets (APs; aspirin, clopidogrel), and/or anticoagulants (ACs; warfarin, direct oral ACs [DOACs; dabigatran, rivaroxaban, apixaban]) to prevent thromboembolic events must be carefully weighed against the risk of intracranial hemorrhage (ICH) with trauma. The goal of this study was to assess the risk of sustaining a traumatic brain injury (TBI), ICH, and poorer outcomes in relation to AT use among all patients 65 years or older presenting to a single institution with head trauma. METHODS: Data were collected from all head trauma patients 65 years or older presenting to the authors' supraregional tertiary trauma center over a 24-month period and included age, sex, injury mechanism, medical history, international normalized ratio, Glasgow Coma Scale (GCS) score, ICH presence and type, hospital admission, reversal therapy, surgery, discharge destination, Extended Glasgow Outcome Scale (GOSE) score at discharge, and mortality. RESULTS: A total of 1365 head trauma patients 65 years or older were included; 724 were on AT therapy (413 on APs, 151 on ACs, 59 on DOACs, 48 on 2 APs, 38 on AP+AC, and 15 on AP+DOAC) and 641 were not. Among all head trauma patients, the risk of sustaining a TBI was associated with AP use after adjusting for covariates. Of the 731 TBI patients, those using ATs had higher rates of ICH (p <0.0001), functional dependency at discharge (GOSE score ≤ 4; p < 0.0001), and mortality (p < 0.0001). Elevated rates of ICH progression on follow-up CT scanning were observed in patients in the warfarin monotherapy (OR 5.30, p < 0.0001) and warfarin + AP (OR 6.15, p = 0.0011). Risk of mortality was not associated with single antiplatelet use but was notably high with 2 APs (OR 4.66, p = 0.0056), warfarin (OR 5.18, p = 0.0003), and DOAC use (OR 5.09, p = 0.0149). CONCLUSIONS: Elderly trauma patients on ATs, especially combination therapy, are at elevated risk of ICH and poor outcomes compared with those not on AT therapy. While both AP and warfarin use alone and in combination were associated with significantly elevated odds of sustaining an ICH among TBI patients, only warfarin use was a predictor of hemorrhage progression on follow-up scans. The use of a single AP was not associated with mortality; however, the combination of both aspirin and clopidogrel was. Warfarin and DOAC users had comparable mortality rates; however, DOAC users had lower rates of ICH progression, and fewer survivors were functionally dependent at discharge than were warfarin users. DOACs are an overall safer alternative to warfarin for patients at high risk of falls.
引用
- Scotti P, Séguin C, Lo BWY, et al. Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes. J Neurosurg. 2019. PMID: 31277068. doi:10.3171/2019.4.JNS19252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。